NEVRO CORP

 NVROのチャート


 NVROの企業情報

symbol NVRO
会社名 Nevro Corp (NEVRO CORP)
分野(sector)   
産業(industry)   
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 ネブロ(Nevro Corp)は医療機器の提供者である。同社は慢性疼痛患者の生活の質を改善する製品を提供することに重点を置く。同社は慢性疼痛の治療のための神経調節プラットフォームであるSenza脊髄電気刺激(SCS)システムを開発・商品化する。同社のHF10療法は慢性疼痛の治療のための神経調節溶液を送達するように設計される。HF10療法は患者が異常感覚を伴わずに持続的鎮痛軽減を達成することを可能にし、不快なショッキングまたは激しい感覚を避けることができる。HF10療法は解剖学的リードの配置に依存する。Senzaシステムは2ヘルツ(Hz)から10000 Hzまでの電気インパルスを生成する。  ネブロは、米国の医療機器メ―カ―。慢性疼痛の治療のための神経調節プラットフォ―ムを開発し、商品化。同社の製品「SENZA」システムは、HF10治療を提供する脊髄刺激(SCS)システムである。SENZAは、10kHzの波形刺激を出すHF10治療に加え、2Hzから10kHzの電気刺激が出るように設計。感覚異常を起こさずに痛みを軽減する。  Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in =65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.
本社所在地 1800 Bridge Parkway Redwood City CA 94065 USA
代表者氏名 D.Keith Grossman
代表者役職名 President Chief Executive Officer Director
電話番号 +1 650-251-0005
設立年月日 38777
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 804人
url www.nevro.com
nasdaq_url
adr_tso
EBITDA (百万ドル) -37.85600
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 1949.35500
売上高 (百万ドル) 387.28900
企業価値(EV) (百万ドル) 1837.20200
当期純利益 (百万ドル) -49.20500
決算概要 BRIEF: For the fiscal year ended 31 December 2018 Nevro Corp revenues increased 19% to $387.3M. Net loss increased 34% to $49.2M. Revenues reflect United States segment increase of 22% to $321.8M. Higher net loss reflects Selling/General/Admin. Expense - Balanci increase of 19% to $238.5M (expense) Research and Development Expense - Bal increase of 29% to $42.6M (expense).

 NVROのテクニカル分析


 NVROのニュース

   Why the Service Neuroendoscopy Devices Market is set to explode? Top Companies: Nevro Corporation, Ackermann Instrumente GmbH, Adeor medical AG, B. Braun Aesculap  2021/09/01 07:14:42 OpenPR
Neuroendoscopy Devices Market Size | 2021 Covid-19 Impact On Healthcare Industry Global Analysis By Size, Trends, Growth, Share, Business, Key Players, Merger, Statistics, Competitive Landscape, And Regional Forecast To 2028 is latest study published by Fortune Business Insights. The Global
   Implantable Neurostimulation Devices Market Covering Growth Elements and Future Trends by 2027, Players - LivaNova, Nevro, NeuroPace, Beijing Pins, Synapse Biomedical, St. Jude Medical (Abbott)  2021/08/27 12:25:32 OpenPR
The Implantable Neurostimulation Devices Market is expected to grow at a CAGR of 6.1 % and is poised to reach $XX Billion by 2027 as compared to $XX Billion in 2020 The research report on the Implantable Neurostimulation Devices Market fabricated
   Spinal Cord Stimulation System Market Marvelous Growth with Fantastic Rate During the Forecast Period with Key Players - Boston Scientific, Nevro, Spinal Modulation.  2021/08/25 12:51:35 OpenPR
The Spinal Cord Stimulation System Market is expected to grow at a CAGR of 8.9%. The factors leading to this extraordinary growth is attributed to various market dynamics discussed in the report. Our experts have examined the market from a
   Bridger Management, Llc Buys Centene Corp, Nevro Corp, Post Holdings Partnering Corp, Sells HCA ...  2021/08/24 20:38:21 GuruFocus
Related Stocks: CLVT , QTRX , DXCM , CNC , NVRO , PSPC.U , LIVN , CHFW.U , NEXI , MSFT , FCNCA , DRNA , SQZ , DMTK ,
   Nevro Corp (NVRO): Price Down $-3.45 (-3.13)% Over Past Day, Down $-0.25 (-0.23)% Over Past Hour  2021/08/18 15:18:43 ETF Daily News
This is a reversal of the price action on the previous day, in which price moved up. The post Nevro Corp (NVRO): Price Down $-3.45 (-3.13)% Over Past Day, Down $-0.25 (-0.23)% Over Past Hour appeared first on ETF Daily News .
   Here is What Hedge Funds Think About Nevro Corp (NVRO)  2021/07/06 15:37:57 Insider Monkey
   Insights on the Pain Management Devices Global Market to 2026 - Key Motivators, Restraints and Opportunities  2021/07/02 08:53:00 Intrado Digital Media
Dublin, July 02, 2021 (GLOBE NEWSWIRE) -- The "Global Pain Management Devices Market 2020-2026" report has been added to ResearchAndMarkets.com''s offering. The global pain management devices market is growing at a considerable CAGR of 7.3% during the forecast period (2021-2027). The increasing prevalence of chronic diseases along with the easy availability of technically advanced pain management devices in the market are the key factors to drive the growth of the global pain management devices market. Supportive reimbursement policies and adverse effects of pain medications are some other factors that are contributing to the growth of the market. However, certain factors are affecting the growth of the market. The high cost of pain management devices, lack of awareness regarding the availability of pain management devices, insufficiency of a pain specialist in underdeveloped and some emerging economies are some key factors that may restrain the growth of the pain management devices market globally.
   A Look Into Nevro''s Debt  2021/06/28 13:17:33 Benzinga
Over the past three months, shares of Nevro (NYSE: NVRO ) increased by 18.38%. Before having a look at the importance of debt, let us look at how much debt Nevro has. Nevro''s Debt Based on Nevro''s financial statement as of May 5, 2021, long-term debt is at $144.04 million and current debt is at $171.00 million, amounting to $315.03 million in total debt. Adjusted for $86.54 million in cash-equivalents, the company''s net debt is at $228.50 million. Let''s define some of the terms we used in the paragraph above. Current debt is the portion of a company''s debt which is due within 1 year, while long-term debt is Full story available on Benzinga.com
   Pain Management Devices Market Value to Increase by US$ 8,388.67 million in the Forecast Period 2021-2028 At A Rate (CAGR) Of 8.1% with Top Companies Like Halyard Health, Inc, B. Braun Melsungen AG, Neurotech NA, Inc., and Nevro Corp.  2021/06/23 19:32:10 OpenPR
Pain management devices are used for managing or controlling the pain caused due to medical conditions like arthritis, injury, cancer, and others. Devices for pain management are used according to the severity of the pain; these devices are widely used
   Nevro Announces SENZA-PDN Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions  2021/06/22 10:00:00 PR Newswire
REDWOOD CITY, Calif., June 22, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized
   Spinal Cord Stimulation Devices Market Outlook, Industry Size, Market Share, Forecast Till 2028 | Boston, Scientific and corporation, Medtronic plc, Nevro corp  2021/03/04 12:43:28 OpenPR
Allied Market Research (USA, Oregon, Portland) Published Latest Report titled, ‘Spinal Cord Stimulation Devices Market: Global Opportunity Analysis and Industry Forecast 2020-2027’. The Spinal Cord Stimulation Devices Market is expected to witness growth in upcoming years due to factors such as
   Nevro (NYSE:NVRO) Announces Quarterly Earnings Results  2021/02/26 18:24:41 Transcript Daily
Nevro (NYSE:NVRO) announced its quarterly earnings results on Tuesday. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.12, MarketWatch Earnings reports. Nevro had a negative return on equity of 30.25% and a negative net margin of 24.46%. Shares of Nevro stock […]
   Nevro Reports Fourth Quarter and Full Year 2020 Financial Results  2021/02/24 21:05:00 PR Newswire
REDWOOD CITY, Calif., Feb. 24, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported its financial results for the fourth quarter and full year ended December…
   Nevro to Present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference  2021/02/01 12:00:00 PR Newswire
REDWOOD CITY, Calif., Feb. 1, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present…
   Nevro to Report Fourth Quarter and Full-Year 2020 Financial Results  2021/01/27 12:00:00 PR Newswire
REDWOOD CITY, Calif., Jan. 27, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter…

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 NEVRO CORP NVRO )

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)